News
Merkel cell carcinoma responds to immunotherapy
The PD-1 inhibitor pembrolizumab and intratumoral injections of IL-12 produced durable responses in patients with advanced disease.
News
Perioperative Measures Predict Child’s Ability to Cope
Major Finding: A preoperative child distress increase of 2 units was associated with a 4.6-fold increase in the odds of having severe pain as...
News
Spine Pain + Fibromyalgia Flag Resistance to Standard Therapy
Major Finding: Patients with axial spine pain at a tertiary pain center who met criteria for fibromyalgia tended to rate opioids as less effective...
News
Mortality Greatest With Recurrence of Papillary Type Thyroid Cancer
Major Finding: Patients who recurred with papillary thyroid cancer were significantly more likely to die of thyroid cancer as compared to...
News
Two-Year Data Indicate MitraClip Safety, Durability
Major Finding: At 2 years, the composite primary efficacy endpoint of freedom from death, MV surgery for valve dysfunction (for device patients)...
News
Link Between Proton Pump Inhibitors, Hip Fractures Confirmed
Major Finding: Regular use of PPIs posed fracture risks of 35%-45% when adjusted for age, calcium intake, and body mass index.
News
Link Between Proton Pump Inhibitors, Hip Fractures Confirmed
Major Finding: Regular use of PPIs posed fracture risks of 35%-45% when adjusted for age, calcium intake, and body mass index.
News
Findings Murky on Extending Interval Between Sigmoidoscopies
Major Finding: The mean incidence rate of distal CRC during years 6-10 was approximately twice as high as that in years 1-5.
News
Findings Murky on Extending Interval Between Sigmoidoscopies
Major Finding: The mean incidence rate of distal CRC during years 6-10 was approximately twice as high as that in years 1-5.